Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Anticancer Immunity with Physical Treatment Modalities
share announcement

Anticancer Immunity with Physical Treatment Modalities

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 1 June 2024 | Viewed by 2045

Special Issue Editor

Dr. Sander Bekeschus

E-Mail Website
Guest Editor
ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany
Interests: redox medicine; immunology; cancer; cold physical plasma; reactive oxygen and nitrogen species; redox signaling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Physical treatment modalities are integral to adjuvant and neoadjuvant treatment schemes in oncology. In this context, numerous technologies are being experimentally and clinically investigated, such as radiotherapy, photodynamic therapy, cryotherapy, proton therapy, hyperthermia, pulsed electric field (PEF)-mediated electroporation (within electrochemotherapy), and gas plasma technology (also referred to as cold physical plasma, cold atmospheric pressure plasma, or nonthermal plasma). In recent years, many of these approaches have been suggested to support the cancer immunity cycle by inducing immunogenic cancer cell death (ICD) in conjunction with DAMPs (damage-associated molecular patterns). In combination with cancer immunotherapies, this may harness the power of antitumor immunity for promoting anticancer treatment responses. Submissions to this SI should focus on ICD-inducing physical modalities, potentially in the context of combination therapies, and molecular and immunological mechanisms thereof.

Dr. Sander Bekeschus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunity cycle
  • cryotherapy
  • gas plasma technology
  • hyperthermia
  • immunogenic cell death (ICD)
  • photodynamic therapy
  • proton therapy
  • pulsed electric fields
  • radiotherapy
  • ROS

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 1504 KiB  
Review
Modulation of the Tumor-Associated Immuno-Environment by Non-Invasive Physical Plasma
by Sarah Förster, Yuequn Niu, Benedikt Eggers, Marjan Nokhbehsaim, Franz-Josef Kramer, Sander Bekeschus, Alexander Mustea and Matthias B. Stope
Cancers 2023, 15(4), 1073; https://doi.org/10.3390/cancers15041073 - 08 Feb 2023
Cited by 2 | Viewed by 1609
Abstract
Over the past 15 years, investigating the efficacy of non-invasive physical plasma (NIPP) in cancer treatment as a safe oxidative stress inducer has become an active area of research. So far, most studies focused on the NIPP-induced apoptotic death of tumor cells. However, [...] Read more.
Over the past 15 years, investigating the efficacy of non-invasive physical plasma (NIPP) in cancer treatment as a safe oxidative stress inducer has become an active area of research. So far, most studies focused on the NIPP-induced apoptotic death of tumor cells. However, whether NIPP plays a role in the anti-tumor immune responses need to be deciphered in detail. In this review, we summarized the current knowledge of the potential effects of NIPP on immune cells, tumor–immune interactions, and the immunosuppressive tumor microenvironment. In general, relying on their inherent anti-oxidative defense systems, immune cells show a more resistant character than cancer cells in the NIPP-induced apoptosis, which is an important reason why NIPP is considered promising in cancer management. Moreover, NIPP treatment induces immunogenic cell death of cancer cells, leading to maturation of dendritic cells and activation of cytotoxic CD8+ T cells to further eliminate the cancer cells. Some studies also suggest that NIPP treatment may promote anti-tumor immune responses via other mechanisms such as inhibiting tumor angiogenesis and the desmoplasia of tumor stroma. Though more evidence is required, we expect a bright future for applying NIPP in clinical cancer management. Full article
(This article belongs to the Special Issue Anticancer Immunity with Physical Treatment Modalities)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop